From Genes to Medicines: Unraveling the Biosynthesis and Biogenesis of Secondary Metabolites

Fuente: Zenodo
Salvato in:
Dettagli Bibliografici
Autore principale: natural product chemistry
Natura: Recurso digital
Lingua:inglese
Pubblicazione: Zenodo 2026
Soggetti:
Accesso online:
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1866901469148479488
author natural product chemistry
author_facet natural product chemistry
contents Secondary metabolites are specialized, low-molecular-weight organic compounds produced by plants and microorganisms. While not strictly essential for basic growth, they play indispensable ecological roles in defense, environmental adaptation, and symbiotic signaling. Because of their immense structural diversity and potent biological activities, these compounds are highly valued in medicine, agriculture, and industry. This extensive review details the fundamental biochemical routes responsible for their creation, including the shikimic acid, mevalonate/methylerythritol phosphate, and acetate-malonate pathways. It also explores the complex molecular assembly lines governed by polyketide synthases (PKS), nonribosomal peptide synthetases (NRPS), and terpene cyclases that generate vast chemical diversity. A major bottleneck in natural product discovery is that many biosynthetic gene clusters (BGCs) remain silent or unexpressed under standard laboratory conditions, and native plants often produce these compounds in minute quantities. To address these hurdles, the article outlines a suite of advanced research methodologies. Genome mining, powered by bioinformatics tools like antiSMASH and reference databases like MIBiG, enables the in silico prediction and genetic dereplication of BGCs, allowing researchers to prioritize novel pathways and avoid redundant discoveries. Furthermore, multi-omics integration (genomics, transcriptomics, metabolomics) and machine learning algorithms facilitate the de novo prediction of metabolic networks and bioactivity. To translate these genetic blueprints into viable clinical candidates, researchers employ synthetic biology and metabolic engineering. Techniques such as heterologous expression in optimized prokaryotic or fungal chassis allow for scalable production. Additionally, non-genetic strategies like the One Strain Many Compounds (OSMAC) approach, microbial co-cultivation, and chemical elicitation in plant cell cultures mimic natural ecological stressors to successfully activate cryptic BGCs and dramatically enhance metabolite yields. By bridging the gap between genomic potential and chemical reality, these integrated approaches provide a robust framework for accelerating the discovery and sustainable production of next-generation therapeutics. Source: https://www.natprodchem.com/posts/from-genes-to-medicines-unraveling-the-biosynthesis-and-biogenesis-of-secondary-metabolites
format Recurso digital
id zenodo_https___doi_org_10_5281_zenodo_19658985
institution Zenodo
language eng
publishDate 2026
publisher Zenodo
record_format zenodo
spellingShingle From Genes to Medicines: Unraveling the Biosynthesis and Biogenesis of Secondary Metabolites
natural product chemistry
secondary metabolites
biosynthesis
genome mining
metabolic engineering
biosynthetic gene clusters
multi-omics
polyketide synthases
elicitation
Secondary metabolites are specialized, low-molecular-weight organic compounds produced by plants and microorganisms. While not strictly essential for basic growth, they play indispensable ecological roles in defense, environmental adaptation, and symbiotic signaling. Because of their immense structural diversity and potent biological activities, these compounds are highly valued in medicine, agriculture, and industry. This extensive review details the fundamental biochemical routes responsible for their creation, including the shikimic acid, mevalonate/methylerythritol phosphate, and acetate-malonate pathways. It also explores the complex molecular assembly lines governed by polyketide synthases (PKS), nonribosomal peptide synthetases (NRPS), and terpene cyclases that generate vast chemical diversity. A major bottleneck in natural product discovery is that many biosynthetic gene clusters (BGCs) remain silent or unexpressed under standard laboratory conditions, and native plants often produce these compounds in minute quantities. To address these hurdles, the article outlines a suite of advanced research methodologies. Genome mining, powered by bioinformatics tools like antiSMASH and reference databases like MIBiG, enables the in silico prediction and genetic dereplication of BGCs, allowing researchers to prioritize novel pathways and avoid redundant discoveries. Furthermore, multi-omics integration (genomics, transcriptomics, metabolomics) and machine learning algorithms facilitate the de novo prediction of metabolic networks and bioactivity. To translate these genetic blueprints into viable clinical candidates, researchers employ synthetic biology and metabolic engineering. Techniques such as heterologous expression in optimized prokaryotic or fungal chassis allow for scalable production. Additionally, non-genetic strategies like the One Strain Many Compounds (OSMAC) approach, microbial co-cultivation, and chemical elicitation in plant cell cultures mimic natural ecological stressors to successfully activate cryptic BGCs and dramatically enhance metabolite yields. By bridging the gap between genomic potential and chemical reality, these integrated approaches provide a robust framework for accelerating the discovery and sustainable production of next-generation therapeutics. Source: https://www.natprodchem.com/posts/from-genes-to-medicines-unraveling-the-biosynthesis-and-biogenesis-of-secondary-metabolites
title From Genes to Medicines: Unraveling the Biosynthesis and Biogenesis of Secondary Metabolites
topic secondary metabolites
biosynthesis
genome mining
metabolic engineering
biosynthetic gene clusters
multi-omics
polyketide synthases
elicitation
url https://doi.org/10.5281/zenodo.19658985